Skip to main content
Advertising

Originally published May 10, 2013 at 8:48 AM | Page modified May 10, 2013 at 8:49 AM

  • Share:
             
  • Comments (0)
  • Print

FDA approves once-a-day inhaler from Glaxo

The Food and Drug Administration says it has approved a new once-a-day inhaler drug from GlaxoSmithKline for patients with chronic lung disease.

The Associated Press

Most Popular Comments
Hide / Show comments
No comments have been posted to this article.
Start the conversation >

advertising

WASHINGTON —

The Food and Drug Administration says it has approved a new once-a-day inhaler drug from GlaxoSmithKline for patients with chronic lung disease.

The agency cleared the Breo Ellipta inhaler for long-term use and to control flare-ups in patients with chronic obstructive pulmonary disorder, often called smoker's cough. The lung ailment can cause a number of breathing problems, including chronic bronchitis and emphysema.

Breo Ellipta delivers a combination of two drugs that reduce inflammation in the lungs and relax airways to ease breathing. The drug carries a warning that it is not approved for asthma.

Glaxo, a leader in respiratory medicine, already sells the asthma treatment Advair, its best-selling product with more than $4 billion in sales per year. The British drugmaker collaborated on the inhaler with South San Francisco-based Theravance.

News where, when and how you want it

Email Icon

The Seattle Times wins top award for multimedia storytelling

The Seattle Times wins top award for multimedia storytelling

Our Sea Change series received a prestigious 2015 DuPont-Columbia award for showcasing the power of storytelling on the Web. Experience the report here.

Advertising

Advertising

The Seattle Times Historical Archives

Browse our newspaper page archives from 1900-1984


Advertising
The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►